BAM
CKPT

Belpointe Asset Management’s Checkpoint Therapeutics CKPT Stock Holding History

Belpointe Asset Management’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-85
Closed -$191 – 1063
2023
Q1 		$191 Hold
85
– – ﹤0.01% 3680
2022
Q4 		$435 Buy
+85
New +$612 ﹤0.01% 3566

Other funds holding CKPT

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

Belpointe Asset Management's CKPT Position: Q2 2023 in Review

Belpointe Asset Management sold out of Checkpoint Therapeutics (CKPT) in Q2 2023, closing a stake of 85 shares — an estimated $191 sold.

Belpointe Asset Management first reported a position in CKPT in Q4 2022 and held it in 2 quarters. The position peaked at $435 in Q4 2022. 34 funds tracked by Wall St. Rank hold CKPT as of Q2 2023.

  • Belpointe Asset Management reported no remaining Checkpoint Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 85 Checkpoint Therapeutics shares in Q2 2023, an estimated $191.
  • Belpointe Asset Management first reported a position in Checkpoint Therapeutics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Checkpoint Therapeutics position peaked at $435 in Q4 2022.
  • 34 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.